Correlation Engine 2.0
Clear Search sequence regions


  • adult (1)
  • GPCR (1)
  • gtpase (1)
  • Gαi (1)
  • Gαq (1)
  • humans (1)
  • levodopa (5)
  • levodopa (2)
  • mice (1)
  • movements (6)
  • N OFQ (3)
  • nociceptin (3)
  • nociceptin (1)
  • nociceptin receptor (1)
  • opioid (4)
  • opioid receptor (4)
  • rats (2)
  • receptors opioid (3)
  • RGS19 (1)
  • RGS4 (11)
  • signal (3)
  • subunits (1)
  • Sizes of these terms reflect their relevance to your search.

    Regulator of G-protein signalling 4 (RGS4) is a signal transduction protein that accelerates intrinsic GTPase activity of Gαi/o and Gαq subunits, suppressing GPCR signalling. Here, we investigate whether RGS4 modulates nociceptin/orphanin FQ (N/OFQ) opioid (NOP) receptor signalling and if this modulation has relevance for l-Dopa-induced dyskinesia. HEK293T cells transfected with NOP, NOP/RGS4 or NOP/RGS19 were challenged with N/OFQ and the small-molecule NOP agonist AT-403, using D1-stimulated cAMP levels as a readout. Primary rat striatal neurons and adult mouse striatal slices were challenged with either N/OFQ or AT-403 in the presence of the experimental RGS4 chemical probe, CCG-203920, and D1-stimulated cAMP or phosphorylated extracellular signal regulated kinase 1/2 (pERK) responses were monitored. In vivo, CCG-203920 was co-administered with AT-403 and l-Dopa to 6-hydroxydopamine hemilesioned rats, and dyskinetic movements, striatal biochemical correlates of dyskinesia (pERK and pGluR1 levels) and striatal RGS4 levels were measured. RGS4 expression reduced NOFQ and AT-403 potency and efficacy in HEK293T cells. CCG-203920 increased N/OFQ potency in primary rat striatal neurons and potentiated AT-403 response in mouse striatal slices. CCG-203920 enhanced AT-403-mediated inhibition of dyskinesia and its biochemical correlates, without compromising its motor-improving effects. Unilateral dopamine depletion caused bilateral reduction of RGS4 levels, which was reversed by l-Dopa. l-Dopa acutely up-regulated RGS4 in the lesioned striatum. RGS4 physiologically inhibits NOP receptor signalling. CCG-203920 enhanced NOP responses and improved the antidyskinetic potential of NOP receptor agonists, mitigating the effects of striatal RGS4 up-regulation occurring during dyskinesia expression. This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc. © 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

    Citation

    Clarissa A Pisanò, Daniela Mercatelli, Martina Mazzocchi, Alberto Brugnoli, Ilaria Morella, Stefania Fasano, Nurulain T Zaveri, Riccardo Brambilla, Gerard W O'Keeffe, Richard R Neubig, Michele Morari. Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesia. British journal of pharmacology. 2023 Apr;180(7):927-942

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34767639

    View Full Text